National Recognition for Innovation in Personalized Oncology.
Odimma Therapeutics was selected as one of France’s “100 Start-ups to Invest in 2021”, a prestigious ranking published by Challenges, one of the country’s leading business and economic magazines.
The recognition highlighted Odimma’s innovative approach to personalized cancer immunotherapy and its ambition to transform precision oncology through next-generation immune-based therapies tailored to each patient’s tumor profile.
Being included in this national selection reflected the growing confidence of the French innovation ecosystem in Odimma’s scientific platform and long-term development strategy, reinforcing the company’s position as an emerging player in biotechnology and personalized medicine.
